Table 3.

Univariate Cox Regression survival analysis.

	Model 1: Unadjusted	Model 2: Adj. for age and gender	Model 3: Model 2 +CFS-adjusted
	HR (95%CI)	HR (95%CI)	HR (95%CI)
Hemoglobin, ref. 1 (6.9–10.8)
2 (10.9–12.5)	1.19 (0.85–1.67)	1.25 (0.89–1.75)	1.29 (0.91–1.80)
3 (12.6–18.9)	1.66 (1.19–2.29)	1.61 (1.16–2.23)	1.69 (1.21–2.35)
% Neutrophils, ref. 1 (29.0–73.7)
2 (73.8–85.4)	2.73 (1.72–4.33)	2.58 (1.63–4.10)	2.49 (1.57–3.96)
3 (85.5–97.8)	6.68 (4.38–10.18)	5.92 (3.87–9.05)	5.66 (3.69–8.69)
# Neutrophils, ref. 1 (0.57–4.82)
2 (4.85–7.95)	0.97 (0.66–1.42)	0.88 (0.60–1.30)	0.88 (0.60–1.29)
3 (7.98–46.60)	2.48 (1.78–3.45)	2.06 (1.47–2.88)	1.98 (1.41–2.78)
% Lymphocytes, ref. 1 (0.7–8.9)
2 (9.0–17.5)	0.35 (0.26–0.48)	0.37 (0.27–0.51)	0.36 (0.26–0.50)
3 (17.6–54.9)	0.20 (0.13–0.29)	0.23 (0.15–0.34)	0.24 (0.16–0.37)
# Lymphocytes, ref. 1 (0.12–0.77)
2 (0.78–1.26)	0.52 (0.38–0.70)	0.56 (0.41–0.76)	0.57 (0.42–0.77)
3 (1.27–12.99)	0.30 (0.21–0.43)	0.34 (0.24–0.49)	0.35 (0.25–0.51)
% Eosinophils, ref. 1 (0–0.09)
2 (0.1–0.5)	0.53 (0.39–0.71)	0.51 (0.38–0.69)	0.51 (0.38–0.69)
3 (0.6–11.1)	0.16 (0.10–0.25)	0.17 (0.11–0.26)	0.17 (0.11–0.26)
# Eosinophils, ref. 1 (0.00)
2 (0.01–0.05)	0.38 (0.28–0.52)	0.37 (0.27–0.51)	0.37 (0.27–0.51)
3 (0.06–0.71)	0.16 (0.10–0.24)	0.16 (0.10–0.24)	0.16 (0.11–0.25)
% Basophils, ref. 1 (0.0–0.1)
2 (0.2)	0.86 (0.62–1.20)	0.84 (0.61–1.17)	0.85 (0.61–1.19)
3 (0.3–2.3)	0.59 (0.40–0.87)	0.66 (0.45–0.97)	0.69 (0.46–1.02)
# Basophils, ref. 1 (0.00–0.01)
2 (0.02)	1.21 (0.88–1.66)	1.21 (0.88–1.66)	1.22 (0.89–1.67)
3 (0.03–0.29)	0.84 (0.56–1.24)	0.86 (0.58–1.28)	0.86 (0.58–1.28)
D-dimer, ref. 1 (190–830)
2 (840–1930)	0.98 (0.68–1.42)	0.95 (0.66–1.37)	0.95 (0.66–1.38)
3 (1940–35000)	1.27 (0.89–1.82)	1.23 (0.86–1.76)	1.18 (0.83–1.69)
eGFR, ref. 1 (3–51)
2 (52–80)	0.49 (0.36–0.67)	0.49 (0.36–0.67)	0.54 (0.39–0.74)
3 (81–90)	0.29 (0.21–0.42)	0.35 (0.24–0.50)	0.35 (0.24–0.51)
Glucose, ref. 1 (39–95)
2 (96–128)	1.15 (0.77–1.73)	1.11 (0.74–1.65)	1.12 (0.75–1.67)
3 (129–880)	1.65 (1.13–2.43)	1.65 (1.13–2.41)	1.58 (1.08–2.32)
Sodium, ref. 1 (115–138)
2 (139–142)	0.89 (0.61–1.31)	0.92 (0.63–1.36)	0.94 (0.64–1.38)
3 (143–173)	3.19 (2.35–4.33)	2.83 (2.07–3.88)	2.73 (1.99–3.75)
Potassium, ref. 1 (2.0–3.9)
2 (4.0–4.5)	0.71 (0.51–0.98)	0.78 (0.56–1.08)	0.79 (0.57–1.10)
3 (4.6–7.9)	1.06 (0.77–1.45)	1.16 (0.85–1.59)	1.19 (0.86–1.63)
NT-proBNP, ref. 1 (14–796)
2 (798–2579)	1.92 (1.24–2.98)	1.76 (1.13–2.74)	1.69 (1.08–2.65)
3 (2580–70000)	3.37 (2.27–5.01)	2.77 (1.84–4.16)	2.67 (1.77–4.04)
CRP, ref. 1 (0.1–2.1)
2 (2.2–7.1)	1.84 (1.22–2.77)	1.69 (1.12–2.55)	1.62 (1.07–2.46)
3 (7.2–34.6)	3.92 (2.69–5.71)	3.58 (2.45–5.21)	3.31 (2.26–4.85)
PCT, ref. 1 (0.05)
2 (0.06–0.19)	2.05 (1.33–3.15)	1.87 (1.21–2.89)	1.84 (1.19–2.84)
3 (0.20–189.55)	4.31 (2.92–6.38)	4.06 (2.74–6.02)	3.96 (2.65–5.90)
IL-6, ref. 1 (1.5–20.5)
2 (20.6–57.5)	1.39 (0.86–2.26)	1.27 (0.79–2.05)	1.17 (0.72–1.90)
3 (57.9–804.2)	2.10 (1.33–3.32)	1.93 (1.23–3.03)	1.86 (1.17–2.94)
Ferritin, ref. 1 (15–397)
2 (403–804)	1.03 (0.70–1.51)	0.99 (0.68–1.44)	0.98 (0.67–1.43)
3 (805–7514)	1.64 (1.14–2.35)	1.60 (1.10–2.31)	1.53 (1.05–2.22)
NLR, ref. 1 (0.43–4.22)
2 (4.25–9.23)	1.57 (1.03–2.41)	1.47 (0.96–2.26)	1.42 (0.92–2.17)
3 (9.27–73.10)	4.50 (3.10–6.55)	3.85 (2.64–5.64)	3.65 (2.48–5.36)
dNLR, ref. 1 (−605 to 1.31)
2 (1.32–3.64)	0.74 (0.51–1.08)	0.74 (0.51–1.08)	0.73 (0.50–1.06)
3 (3.68–274)	2.07 (1.53–2.81)	1.99 (1.46–2.70)	1.89 (1.39–2.57)
PLR, ref. 1 (4.56–165.79)
2 (165.83–294.23)	1.03 (0.72–1.48)	1.00 (0.70–1.44)	1.02 (0.71–1.47)
3 (296.12–1660.00)	2.00 (1.45–2.77)	2.03 (1.47–2.81)	1.91 (1.38–2.64)
LMR, ref. 1 (0.26–1.63)
2 (1.64–2.84)	0.46 (0.33–0.64)	0.48 (0.35–0.67)	0.52 (0.37–0.73)
3 (2.85–38.21)	0.50 (0.36–0.69)	0.55 (0.40–0.77)	0.56 (0.40–0.78)

Notes, CFS, clinical frailty scale; #, absolute count; CRP, C Reactive Protein; PCT, procalcitonin; IL-6, interleukin-6; NLR, neutrophil- to-lymphocyte ratio; dNLR, derived NLR ratio (neutrophil count divided by the result of WBC count minus neutrophil count); PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.